What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

In morning trades, Moderna stock rose nearly 4% to 28.22 ... support rapid response in a future influenza pandemic, and pave the way for COVID-19 combination vaccines," Bancel added. Notably, the ...

Moderna has proven its capability in the COVID-19 vaccines race against the Pfizer/BioNTech partnership. Read more to see the 2022 outlook for MRNA stock.

Covid-19 vaccine giant Moderna (NASDAQ:MRNA) has been on a tear since the second quarter of 2020. It has grown its top line by over 6,500% on a year-over-year basis due to rampant sales of its ...

To get a sense of what could be in store for Moderna in the future, we have to first look at where things stand right now for the company. The best place to start is with the biotech's COVID-19 ...

Moderna’s mRNA COVID-19 vaccine candidate was the first U.S. shot to enter late-stage testing, but that doesn’t necessarily mean it has the brightest future of all.

Despite cost cuts, Moderna posted a second straight quarterly loss. It now sees 2024 sales ranging between $3 billion and $3.5 billion, down from its previous outlook of about $4 billion ...

Moderna is on its way to getting a third mRNA-based vaccine approved by the FDA if the regulatory agency likes the data released Monday for a combination flu-COVID shot.The company said the new ...

Covid-19 vaccine giant Moderna (NASDAQ:MRNA) has been on a tear since the second quarter of 2020. It has grown its top line by over 6,500% on a year-over-year basis due to rampant sales of its ...